| Literature DB >> 22173840 |
Nicolaas I Bohnen1, David S W Djang, Karl Herholz, Yoshimi Anzai, Satoshi Minoshima.
Abstract
Imaging that can detect pathophysiologic change in the brain holds great promise for diagnostic assessment of patients with Alzheimer disease (AD) and dementia. Although a previous metaanalysis centering on literature from 1990 to 2000 showed a summary accuracy of 86% for (18)F-FDG PET for AD diagnosis, the clinical value was considered uncertain because of methodologic shortcomings. Review of the recent literature since 2000 demonstrates that the evidence for (18)F-FDG PET in assessment of dementia has increased with new studies that include autopsy confirmation, wide-diagnostic-spectrum recruitment in primary care settings, historical and prospective cohort studies, and multicenter data analyses. These data support the role of (18)F-FDG PET as an effective and useful adjunct to other diagnostic information in the assessment of patients with symptoms of dementia. Findings are in line with recently revised diagnostic criteria of AD that for the first time recognize the unique role of biomarker evidence in disease definition.Entities:
Mesh：
Substances：
Year: 2011 PMID： 22173840 DOI： 10.2967/jnumed.111.096578
Source DB: PubMed Journal: J Nucl Med ISSN： 0161-5505 Impact factor: 10.057